Donna Reece

2.6k total citations · 1 hit paper
7 papers, 1.2k citations indexed

About

Donna Reece is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Donna Reece has authored 7 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Hematology, 5 papers in Molecular Biology and 5 papers in Oncology. Recurrent topics in Donna Reece's work include Multiple Myeloma Research and Treatments (7 papers), Protein Degradation and Inhibitors (4 papers) and Peptidase Inhibition and Analysis (3 papers). Donna Reece is often cited by papers focused on Multiple Myeloma Research and Treatments (7 papers), Protein Degradation and Inhibitors (4 papers) and Peptidase Inhibition and Analysis (3 papers). Donna Reece collaborates with scholars based in Canada and Spain. Donna Reece's co-authors include Morie A. Gertz, Sergio Giralt, B. Björkstrand, Joan Bladé, Gösta Gahrton, Diana Samson, David H. Vesole, Jane F. Apperley, Hira Mian and Darrell White and has published in prestigious journals such as Nature Medicine, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Donna Reece

6 papers receiving 1.2k citations

Hit Papers

CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION ... 1998 2026 2007 2016 1998 250 500 750 1000

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Donna Reece Canada 3 1.1k 808 636 133 72 7 1.2k
Víctor H. Jiménez‐Zepeda Canada 20 728 0.6× 914 1.1× 588 0.9× 272 2.0× 104 1.4× 102 1.3k
Shebli Atrash United States 13 521 0.5× 403 0.5× 454 0.7× 114 0.9× 112 1.6× 119 752
S. Naucke United States 8 1.4k 1.2× 931 1.2× 674 1.1× 198 1.5× 94 1.3× 10 1.5k
José María Alonso Spain 10 533 0.5× 423 0.5× 233 0.4× 189 1.4× 58 0.8× 19 685
Tommasina Guglielmelli Italy 13 710 0.6× 589 0.7× 441 0.7× 124 0.9× 40 0.6× 31 879
Abdul Hamid Bazarbachi United States 14 550 0.5× 388 0.5× 479 0.8× 107 0.8× 153 2.1× 30 878
Nisha S. Joseph United States 13 645 0.6× 498 0.6× 389 0.6× 107 0.8× 68 0.9× 69 783
Jeana Cromer United States 6 802 0.7× 557 0.7× 413 0.6× 64 0.5× 63 0.9× 6 870
Khalid Mezzi United States 12 499 0.4× 411 0.5× 426 0.7× 68 0.5× 142 2.0× 26 788
DH Vesole United States 11 1.2k 1.0× 557 0.7× 481 0.8× 103 0.8× 299 4.2× 12 1.3k

Countries citing papers authored by Donna Reece

Since Specialization
Citations

This map shows the geographic impact of Donna Reece's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Donna Reece with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Donna Reece more than expected).

Fields of papers citing papers by Donna Reece

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Donna Reece. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Donna Reece. The network helps show where Donna Reece may publish in the future.

Co-authorship network of co-authors of Donna Reece

This figure shows the co-authorship network connecting the top 25 collaborators of Donna Reece. A scholar is included among the top collaborators of Donna Reece based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Donna Reece. Donna Reece is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

7 of 7 papers shown
1.
Masih‐Khan, Esther, Katherine Lajkosz, Sita Bhella, et al.. (2025). Debulking Chemotherapy Abrogates the Risk of Non-Response in Multiple Myeloma Patients with High Tumor Burden Receiving Teclistamab. Clinical Lymphoma Myeloma & Leukemia. 25. S97–S98.
2.
Venner, Christopher P., Peter Duggan, Kevin Song, et al.. (2024). Tandem Autologous Stem Cell Transplantation Does Not Benefit High-Risk Myeloma Patients in the Maintenance Era: Real-World Results from The Canadian Myeloma Research Group Database. Transplantation and Cellular Therapy. 30(9). 889–901. 1 indexed citations
3.
Devasia, Anup J., Esther Masih‐Khan, Jing Yang, et al.. (2024). Incidence and Severity of Hypogammaglobulinemia, and Profile of Infections in Patients with Relapsed Multiple Myeloma Treated with Belantamab Mafodotin. Blood. 144(Supplement 1). 3787–3787. 1 indexed citations
4.
McCurdy, Arleigh, Donna Reece, Martha Louzada, et al.. (2024). Belantamab mafodotin, pomalidomide, and dexamethasone for triple class exposed/refractory relapsed multiple myeloma: a subgroup analysis of the ALGONQUIN trial. Blood Cancer Journal. 14(1). 155–155. 2 indexed citations
5.
Trudel, Suzanne, Arleigh McCurdy, Martha Louzada, et al.. (2024). Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial. Nature Medicine. 30(2). 543–551. 17 indexed citations
7.
Bladé, Joan, Diana Samson, Donna Reece, et al.. (1998). CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION. British Journal of Haematology. 102(5). 1115–1123. 1187 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026